Search clinical trials for: Relapsed AML

Total 7370 results

CASI Pharmaceuticals, Inc.

Completed

Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies

Relapsed or Refractory Hematological Malignancies

Canada
University of Ulm

Terminated

Lenalidomide In Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Germany
Sunnybrook Health Sciences Centre
Merck Frosst Canada Ltd.; Schering-Plough

Terminated

INdians Followed for INtensive Lipid Lowering Treatment and Its safetY (INFINITY)

Hypercholesterolemia

Canada
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension

Hypertension

United States
Nevada Cancer Institute
GlaxoSmithKline; Cephalon

Withdrawn

PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

Chronic Lymphocytic Leukemia (CLL)

United States
Aegera Therapeutics

Terminated

AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

Leukemia

United States, Canada, Germany
Aegera Therapeutics
The Leukemia and Lymphoma Society

Terminated

A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas

Lymphoma, B-Cell | Leukemia, Lymphocytic, Chronic, B-Cell

Canada, United States
Novartis

Completed

Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension

Moderate to Severe Hypertension

Russian Federation, Romania, Singapore, Spain, Germany, Philippines
Novartis

Completed

Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone

Hypertension

Estonia, France, Iceland, India, Italy, Korea, Republic of, Lithuania, Spain, Venezuela
Johannes Gutenberg University Mainz

Unknown

Telmisartan, Amlodipine and Flow Mediated Dilation (TEAMSTAprotect)

Hypertension

Germany
Technische Universität Dresden

Completed

Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)

Myeloid Leukemia | Myelodysplastic Syndrome

Germany
Istituto Giannina Gaslini

Completed

Clove In The Treatment Of Relapsed Or Resistant Acute Leukemia In Children (CLOVE)

Acute Leukemia

Italy
Dana-Farber Cancer Institute

Completed

A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer

Neoplasms

United States
Ullevaal University Hospital
Merck Sharp & Dohme LLC

Completed

Glucose Optimisation With Angiotensin II Antagonist Losartan (GOAAL)

Hypertension

Norway
Sirion Therapeutics, Inc.

Completed

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-004)

Inflammation

United States
Weill Medical College of Cornell University
Eisai Inc.

Completed

Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML

Acute Myeloid Leukemia

United States
Ascenta Therapeutics

Completed

Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | Small Lymphocytic Lymphoma

United States
Brasilia Heart Study Group

Completed

Simvastatin Effect on Inflammation and Endothelial Function After Myocardial Infarction

Myocardial Infarction | Inflammation | Endothelial Dysfunction

Brazil
TSH Biopharm Corporation Limited

Completed

ADDM Study - Amtrel and Co-Diovan in Type 2 Diabetes Mellitus Hypertension Patients With Microalbuminuria

Hypertension | Diabetes Mellitus, Type 2 | Albuminuria

Taiwan
AstraZeneca

Completed

Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)

Acute Myeloid Leukemia

United States, France
Cylene Pharmaceuticals

Unknown

Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
Fondazione EMN Italy Onlus

Terminated

Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients (D-MP)

Myeloma

Italy
Cooperative Study Group A for Hematology

Completed

High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML (ADcomparison)

ACUTE MYELOGENOUS LEUKEMIA

Korea, Republic of
Novartis

Completed

Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension (ASCENT)

Hypertension

United States
Intarcia Therapeutics

Completed

Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment

Chronic Hepatitis C

United States, Puerto Rico
Chong Kun Dang Pharmaceutical

Completed

CKD-828(80/2.5mg) Pharmacokinetic Study_2nd

Hypertension
Novartis

Completed

Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients Hypertension

Hypertension

United States
Novartis Pharmaceuticals

Completed

Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension

Hypertension

Czech Republic, Finland, France, Germany, Hungary, Italy, Poland, Slovakia, Spain, Sweden
Novartis

Completed

Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension

Hypertension

Switzerland
Novartis Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension

Hypertension

Sweden, United States, Peru, Russian Federation, Romania, Mexico, Panama, Spain, Denmark, Italy, Greece, South Africa, Canada, Argentina, Australia, Colombia, Finland, Taiwan
Ramathibodi Hospital
National Health Security Office, Thailand; Ubon Ratchathani Public Health Office... and other collaborators

Unknown

Primary Prevention of Cardiovascular Disease (CVD) in Pre-diabetic & Pre-hypertensive Subjects (PPCVD)

Pre-diabetes | Pre-hypertension

Thailand
Jiangsu Simcere Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension

Essential Hypertension

China
Novartis

Completed

Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension

Essential Hypertension
Novartis

Terminated

Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome (ALTO)

Hypertension With Metabolic Syndrome

United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a Day

Hypertension

France, Tunisia
Janssen Pharmaceutical K.K.

Completed

An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy

Multiple Myeloma
Janssen Pharmaceutical K.K.

Completed

A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients

Multiple Myeloma | Relapse | Refractory
Mayo Clinic
National Cancer Institute (NCI)

Completed

Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm
Pfizer

Completed

CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects

Hepatitis, Chronic Active

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Novartis

Completed

Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy

Hypertension; Hypertrophy, Left Ventricular

Germany
Alcon Research

Completed

Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis

Vasomotor Rhinitis

United States
Novartis

Completed

Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

Hypertension

Sweden, United States, Romania, Denmark, Israel, Italy, Germany, Australia, Canada, Latvia, Lithuania, Turkey
Assistance Publique - Hôpitaux de Paris

Completed

5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS

Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukaemia (AML)

France
Novartis

Completed

Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension (AMAZING)

Hypertension

Germany
InVasc Therapeutics, Inc.

Unknown

Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome (AMORE)

Hypertension

United States
SCRI Development Innovations, LLC
Biogen

Completed

Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma

Non-Hodgkins Lymphoma

United States
SCRI Development Innovations, LLC
CTI BioPharma

Completed

Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Hoosier Cancer Research Network
Genentech, Inc.; Walther Cancer Institute

Completed

A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer

Small Cell Lung Cancer

United States

3

Subscribe